TTR and amyloidosis: Subsequently, Alnylam Pharmaceuticals’ liposomal siRNA drug ONPATTRO® (Cambridge, MA, United States) for hereditary transthyretin-mediated amyloidosis was approved by the FDA in 2018 [34,36].